WALTHAM, Mass., March 09, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read moreWALTHAM, Mass., March 08, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read moreWALTHAM, Mass., March 02, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]
read moreClick here to download the full article[…]
read moreWALTHAM, Mass., Feb. 07, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read moreEGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints WALTHAM, Mass., Feb. 05, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) […]
read moreSarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., Jan. 04, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: […]
read moreFurther Strengthens Global IP Protection for EGP-437 WALTHAM, Mass., Dec. 19, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical […]
read moreOn track to report topline data in 2Q18 and file NDA within 2018 WALTHAM, Mass., Dec. 18, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or […]
read moreWALTHAM, Mass., Nov. 14, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for […]
read more